UM171: Uncovering a New Pathway to Human Blood Stem Cell Self-Renewal
Our laboratory’s work on UM171 connects fundamental discovery with clinical translation. Working closely with Anne Marinier and her medicinal chemistry team at IRIC, we discovered UM171, a small molecule that enables the expansion of human cord-blood stem cells (Fares et al., Science, 2014). We subsequently identified CRL3–KBTBD4 as the essential machinery mediating UM171-induced degradation of the CoREST complex and MYC and provided early evidence that UM171 enhances its association with KBTBD4 (Chagraoui et al., Cell Stem Cell, 2021; Blood 2025). These findings established a mechanistic foundation for subsequent structural studies by other teams that resolved the interface involving KBTBD4 and HDAC1/2. In close collaboration with Sandra Cohen and her clinical colleagues at Hôpital Maisonneuve-Rosemont, and with additional clinical investigators and partners and ExCellThera, we helped translate this discovery into transplantation trials, from the initial phase I/II study (Cohen et al., The Lancet Haematology, 2020) to two single-arm phase II studies reporting encouraging engraftment and disease-control outcomes (Cohen et al., medRxiv, 2026, submitted). This shared effort brings together stem-cell biology, medicinal chemistry and clinical expertise to create new treatment possibilities for patients with blood cancers.











